Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthtech Industry Analysis

UpdatedJun 27, 2026
DataAggregated Company Financials
Companies68
  • 7D8.8%
  • 3M4.1%
  • 1Y-43.3%
  • YTD-22.5%

In the last week, the Healthtech industry is up 2.1%, with Veeva Systems up 12%. In the past year, the industry is down 47%. Looking forward, earnings are forecast to grow by 23% annually.

Industry Valuation and Performance

Has the U.S. Healthtech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 27 Jun 2026US$45.3bUS$14.4b-US$748,582,179.0029.9x-60.5x3.2x
Mon, 25 May 2026US$44.8bUS$13.6b-US$505,606,878.0029.3x-88.6x3.3x
Wed, 22 Apr 2026US$48.3bUS$13.6b-US$417,856,415.0032.1x-115.5x3.6x
Fri, 20 Mar 2026US$49.8bUS$13.6b-US$387,511,468.0033.2x-128.4x3.7x
Sun, 15 Feb 2026US$47.2bUS$13.6b-US$98,008,340.0038.6x-482.1x3.5x
Tue, 13 Jan 2026US$67.3bUS$13.6b-US$102,102,340.0052.4x-659.3x5x
Thu, 11 Dec 2025US$65.4bUS$13.6b-US$119,482,271.0052.3x-547.3x4.8x
Sat, 08 Nov 2025US$78.1bUS$13.1b-US$23,492,903.0061.6x-3325x6x
Mon, 06 Oct 2025US$83.1bUS$13.1b-US$211,110,296.0060x-393.6x6.3x
Wed, 03 Sep 2025US$76.9bUS$13.2b-US$285,313,296.0054.6x-269.4x5.8x
Fri, 01 Aug 2025US$78.0bUS$13.3b-US$608,456,447.0059.5x-128.2x5.9x
Sun, 29 Jun 2025US$78.9bUS$13.2b-US$1,382,394,447.0055.4x-57.1x6x
Tue, 27 May 2025US$67.1bUS$13.1b-US$1,464,882,390.0051.8x-45.8x5.1x
Thu, 24 Apr 2025US$65.3bUS$13.2b-US$1,417,865,959.0050.5x-46x5x
Sat, 22 Mar 2025US$70.5bUS$13.2b-US$1,405,690,435.0058.7x-50.2x5.4x
Mon, 17 Feb 2025US$77.2bUS$12.9b-US$1,604,881,514.0064.4x-48.1x6x
Wed, 15 Jan 2025US$64.5bUS$12.9b-US$1,638,075,364.0052.9x-39.4x5x
Fri, 13 Dec 2024US$69.4bUS$12.9b-US$1,644,592,390.0056.6x-42.2x5.4x
Sun, 10 Nov 2024US$69.3bUS$12.8b-US$1,677,294,370.0061.7x-41.3x5.4x
Tue, 08 Oct 2024US$63.7bUS$14.0b-US$3,264,827,208.0052.6x-19.5x4.6x
Thu, 05 Sep 2024US$65.1bUS$14.0b-US$3,320,563,821.0056.8x-19.6x4.7x
Sat, 03 Aug 2024US$59.1bUS$13.7b-US$3,170,058,711.0051.8x-18.7x4.3x
Mon, 01 Jul 2024US$56.8bUS$13.7b-US$1,909,009,047.0047.6x-29.8x4.2x
Wed, 29 May 2024US$57.6bUS$12.7b-US$1,885,422,856.0046.3x-30.6x4.5x
Fri, 26 Apr 2024US$56.8bUS$12.7b-US$1,618,344,679.0046.4x-35.1x4.5x
Sun, 24 Mar 2024US$64.4bUS$14.3b-US$1,502,658,316.0050.1x-42.9x4.5x
Tue, 20 Feb 2024US$65.2bUS$13.8b-US$5,663,248,794.0062.3x-11.5x4.7x
Thu, 18 Jan 2024US$71.8bUS$18.3b-US$5,780,316,752.0057.3x-12.4x3.9x
Sat, 16 Dec 2023US$68.9bUS$18.3b-US$5,781,192,665.0056.7x-11.9x3.8x
Mon, 13 Nov 2023US$62.2bUS$18.2b-US$5,939,477,037.0049.1x-10.5x3.4x
Wed, 11 Oct 2023US$71.9bUS$18.0b-US$5,559,240,965.0052.9x-12.9x4x
Fri, 08 Sep 2023US$75.2bUS$18.0b-US$5,515,729,389.0051.3x-13.6x4.2x
Sun, 06 Aug 2023US$77.2bUS$17.9b-US$5,602,320,123.0058.3x-13.8x4.3x
Tue, 04 Jul 2023US$76.2bUS$17.7b-US$8,580,469,318.0062.1x-8.9x4.3x
Price to Earnings Ratio

-8.9x


Total Market Cap: US$76.2bTotal Earnings: -US$8,580,469,318.00Total Revenue: US$17.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthtech Industry Price to Earnings3Y Average -131.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 4.7x is higher than the industry's current PS ratio of 3.2x.
Past Earnings Growth
  • The earnings for companies in the Healthcare Services industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 6.7% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-2.65%
Healthcare7.42%
Healthtech8.80%
Healthtech8.80%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VEEV Veeva SystemsUS$171.3611.8%
+US$2.9b		-39.5%PE29.6x
WAY Waystar HoldingUS$19.907.7%
+US$274.3m		-49.9%PE30.3x
HTFL HeartFlowUS$35.656.0%
+US$173.3m		n/aPS16.1x
EVH Evolent HealthUS$5.5122.7%
+US$114.7m		-50.6%PS0.3x
SDGR SchrödingerUS$16.867.0%
+US$82.2m		-18.2%PS4.9x

Latest News

DH
US$0.66
Definitive Healthcare
7D
-13.2%
1Y
-82.7%
SLP
US$18.20
Simulations Plus
7D
-0.2%
1Y
7.9%
Narrative Update • Jun 26

SLP: Takeover Deal And AI Partnerships Will Shape Balanced Outlook

Analysts have reduced their price target for Simulations Plus to $17.25 from $22.33, reflecting updated views on the company's discount rate, revenue growth, profit margins, and future P/E assumptions. What’s in the News for Simulations Plus Altaris, LLC agreed to acquire Simulations Plus, Inc.
AIFF
US$1.32
Firefly Neuroscience
7D
-3.6%
1Y
-54.9%
VEEV
US$171.36
Veeva Systems
7D
11.8%
1Y
-39.5%
CTEV
US$33.15
Claritev
7D
12.7%
1Y
-23.9%
Narrative Update • Jun 25

CTEV: New Contracts And Management Changes Will Support Future Upside Potential

Analysts have trimmed their average price target on Claritev to $61, reflecting a reset from prior expectations near $90. The revised target continues to be associated with support from new coverage initiations, recent management efforts, and recent contract wins cited across recent research.
ITOC
US$0.31
iTonic Holdings
7D
-2.2%
1Y
-98.3%
WAY
US$19.90
Waystar Holding
7D
7.7%
1Y
-49.9%
Narrative Update • Jun 23

WAY: AI-Driven Revenue Integration And Buybacks Will Support Future Rerating

Analysts kept their fair value estimate for Waystar Holding steady at $33.83 while making only marginal tweaks to underlying inputs, indicating fine-tuning of assumptions rather than a change in overall outlook. What’s in the News for Waystar Holding Waystar’s “The State of the Mid-Revenue Cycle” report highlights that 86% of healthcare organizations still rely on manual or disconnected systems.
DOCS
US$20.88
Doximity
7D
2.1%
1Y
-65.8%
Narrative Update • Jun 23

DOCS: AI Investment Year And Healthcare Moat Set To Support Reengagement

The updated Doximity analyst price target edges up slightly to $25.42, as analysts balance concerns about slower digital advertising growth, tougher competition, and heavier AI investment against a still supportive longer term rationale. This is reflected in a modestly higher fair value and P/E assumption.
SDGR
US$16.86
Schrödinger
7D
7.0%
1Y
-18.2%
Narrative Update • Jun 22

SDGR: Hosted Software Shift And 2026 Execution Progress Will Support Upside

Analysts have trimmed their average price target on Schrödinger, with recent cuts such as Morgan Stanley's move from $19 to $17. These revisions reflect updated assumptions around discount rates, profitability, and future P/E expectations.
SCNX
US$0.36
Scienture Holdings
7D
-5.7%
1Y
-61.5%
LFMD
US$4.13
LifeMD
7D
-13.1%
1Y
-70.0%
Narrative Update • Jun 18

LFMD: GLP-1 Virtual Care Expansion Will Support 2026 Revenue Ambitions

Analysts have kept their $9.88 price target on LifeMD broadly unchanged, citing only minor tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in the core valuation view. What’s in the News for LifeMD LifeMD issued earnings guidance for the second quarter, expecting revenue between $47 million and $50 million.
CCLD
US$2.15
CareCloud
7D
-1.4%
1Y
-10.8%
Narrative Update • Jun 16

CCLD: Balance Sheet Reshaping And 2026 Guidance Will Support Bullish Repricing

Analysts have adjusted their price target on CareCloud to $8.00, reflecting updated assumptions around revenue growth, profit margins, discount rate and future P/E that they consider better aligned with the company’s current outlook. What’s in the News for CareCloud CareCloud fully redeemed all outstanding 8.75% Series B Preferred Stock, funded with a new US$50 million credit facility led by Citizens Bank with participation from Provident Bank.
EVH
US$5.51
Evolent Health
7D
22.7%
1Y
-50.6%
Narrative Update • Jun 16

EVH: Rich P/E Assumptions Will Constrain Upside Despite Raised Price Objectives

Analysts have raised their price target on Evolent Health stock to $5.50 from $4.00, citing updated assessments of fair value, growth, margins, and future P/E assumptions. Analyst Commentary Recent research on Evolent Health frames the higher price targets within a mixed backdrop, where some analysts highlight potential upside while others emphasize execution and valuation risks.
TDOC
US$8.39
Teladoc Health
7D
4.0%
1Y
-0.2%
Narrative Update • Jun 15

TDOC: Walmart Distribution And BetterHelp Access Will Shape Balanced Future Outlook

Narrative Update: Teladoc Health Analyst Target Revision Analysts have nudged Teladoc Health's fair value estimate higher, with the implied price target moving from about $7.12 to roughly $7.40 as they factor in updated assumptions on revenue growth, profit margins, and the potential impact of distribution partnerships such as the recently announced Walmart Better Care Services rollout. Analyst Commentary Recent research on Teladoc Health reflects a mixed but active debate, with several firms updating their price targets and views on the company following sector-wide pressure in MedTech and the rollout of new partnerships such as the Walmart Better Care Services arrangement.
HTFL
US$35.65
HeartFlow
7D
6.0%
1Y
n/a
BFRG
US$0.65
Bullfrog AI Holdings
7D
-9.4%
1Y
-56.6%